Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from mouse liver treated with metformin

ABSTRACT: Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes. We examined the effects of metformin, commonly used to treat patients with type 2 diabetes, on liver pathology in a non-diabetic NASH mouse model.

ORGANISM(S): Mus musculus

PROVIDER: GSE35961 | GEO | 2012/02/21

SECONDARY ACCESSION(S): PRJNA152055

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from mouse liver treated with metformin

Project description:Optimal treatment for nonalcoholic steatohepatitis (NASH) has not yet been established, particularly for individuals without diabetes. We examined the effects of metformin, commonly used to treat patients with type 2 diabetes, on liver pathology in a non-diabetic NASH mouse model. Eight-week-old C57BL/6 mice were fed a methionine- and choline-deficient (MCD) + high fat (HF) diet with or without 0.1% metformin for 8 weeks.

2012-02-21 | E-GEOD-35961 | biostudies-arrayexpress

Comparison of circRNA expression profile among the livers of C57BL/6J control mice, high fat diet (HFD) mice and metformin treated mice

Project description:Nonalcoholic fatty liver disease (NAFLD) is a growing worldwide epidemic and an important risk factor for the development of insulin resistance, type 2 diabetes, nonalcoholic steatohepatitis (NASH), and hepatic cellular carcinoma (HCC). Despite the prevalence of NAFLD, lifestyle interventions involving exercise and weight loss are the only accepted treatments for this disease. Over the past years, metformin has been shown to improve NAFLD in preclinical animal models. Several coding and non-coding genes have been suggested to contribute to the metformin treatment mechanism of NAFLD. Circulating RNA (circRNA) is a novel group of non-coding RNAs which may have regulatory role in vivo. This study firstly probe the potential role of circRNA in the treatment of NAFLD by the microarray circRNA expression profiling.

2018-06-21 | GSE94841 | GEO

Comparison of miRNA expression profile among the livers of C57BL/6J control mice, high fat diet (HFD) mice and metformin treated mice

Project description:Nonalcoholic fatty liver disease (NAFLD) is a growing worldwide epidemic and an important risk factor for the development of insulin resistance, type 2 diabetes, nonalcoholic steatohepatitis (NASH), and hepatic cellular carcinoma (HCC). Despite the prevalence of NAFLD, lifestyle interventions involving exercise and weight loss are the only accepted treatments for this disease. Over the past years, metformin has been shown to improve NAFLD in preclinical animal models. Hepatic microRNAs (miRNAs) have been suggested as therapeutic targets because of their involvement in the progression of NAFLD. The aim of this study was to identify miRNAs associated with the regulation of liver lipid metabolism after metformin treatment. We performed computational analysis of the function enrichment and disease association of the differentially expressed miRNAs and their targets. Our analysis may shed light on the novel treatment method for NAFLD.

2018-06-21 | GSE94799 | GEO

Comparison of lncRNA and mRNA expression profile among the livers of C57BL/6J control mice, high fat diet (HFD) mice and metformin treated mice

Project description:Nonalcoholic fatty liver disease (NAFLD) is a growing worldwide epidemic and an important risk factor for the development of insulin resistance, type 2 diabetes, nonalcoholic steatohepatitis (NASH), and hepatic cellular carcinoma (HCC). Despite the prevalence of NAFLD, lifestyle interventions involving exercise and weight loss are the only accepted treatments for this disease. Over the past years, metformin has been shown to improve NAFLD in preclinical animal models. However, whether and how the long non-coding RNAs (lncRNAs) were involved in the progression of NAFLD and the mechanism of metformin treatment were not clearly understood. The aim of this study was to identify lncRNAs associated with the regulation of liver lipid metabolism after metformin treatment. We performed computational analysis of the function enrichment of the differentially expressed lncRNAs and mRNAs. Our analysis also suggested significant co-expression between hepatic lncRNAs and their predicted mRNA targets. Our analysis suggests a noticeable role in the etiology and treatment of NAFLD.

2018-06-21 | GSE94790 | GEO

Importance of AMPK in metformin suppression of liver glucose production

Project description:Metformin is now the most widely prescribed oral anti-diabetic agent worldwide, taken by over 150 million people annually. Although metformin has been used clinically to treat type 2 diabetes for over 60 years. Its mechanism of action remains only partially understood and controversial. In particular, this includes whether AMPK plays a role in metformin suppression of liver glucose production. To address this issue, we knocked out the AMPK catalytic alpha1 and alpha 2 subunits in the liver of HFD-fed adult homozygous mice. These mice were treated with a physiological relevent metformin dose (50 mg/kg/day) for 3 weeks. Liver samples were collected.

2019-11-13 | GSE114234 | GEO

Transcription profiling of mouse finally differentiated 3T3-L1 adipocytes treated with insulin (0 or 100nM)or metformin (0 or 2mM)for 2 and 12 hours

Project description:Finally differentiated 3T3-L1 adipocytes are treated with insulin (0 or 100nM)or metformin (0 or 2mM)for 2 and 12 hours to understand insulin and metformin(an anti-diabetic drug commonly applied for Non-Insulin Dependent Diabetes Mellitus)action in adipose tissues.

2013-01-30 | E-BAIR-8 | biostudies-arrayexpress

Dietary cholesterol promotes fatty liver-associated liver cancer by inducing aberrant genomic expression and mutations

Project description:We investigated the effects of cholesterol on nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC) in diethylnitrosamine-injected mice fed high-fat high-cholesterol (HFHC) diet versus high-fat (HF) alone. mRNA microarray analysis was applied for expressional aberrations.

2018-09-27 | E-MTAB-6002 | biostudies-arrayexpress

6d989d11-209a-4dcf-b685-cb900bf341eb - samples

Project description:Intrahepatic cholangiocyte organoid clone from patients with chronic alcohol consumption, NASH (nonalcoholic steatohepatitis), and PSC (primary sclerosing cholangitis)

| EGAD00001007775 | EGA

Impact of Pretreatment With Metformin on Colorectal Cancer Stem Cells (CCSC) and Related Pharmacodynamic Markers

Project description:Metformin is drug that is normally used to treat people with diabetes. New research has discovered that metformin may also kill cancer stem cells. These cancer stem cells make up only a small portion of a cancer, but may be responsible for resistance to chemotherapy or for causing recurrence of the cancer. The purpose of this study is to determine the effect of metformin on colorectal cancer tumors. The study is designed to develop the methods to test tumors for cancer stem cells and then to determine the difference between treating with metformin and not treating with metformin with regard to the cancer stem cells. This research is investigational because the effect of metformin on cancer stem cells is not known in humans. Also, in patients who are not diabetic, metformin would normally not be given prior to surgery.

| 2113267 | ecrin-mdr-crc

Study of microRNA associated with metformin treatment in a mouse model of NASH(MCD)

Project description:The microRNAs expression was altered with the treatment of metformin in vivo and several microRNAs induced by metformin also may contribute to suppressed of NASH. Using a custom microarray platform, we analyzed the expression levels of 1135 mouse microRNA probes in liver tissue in vivo that were treated with and without metformin.

2015-03-01 | E-GEOD-55523 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data